These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36651953)

  • 1. Relative enhancement index can be used to quantify liver function in cirrhotic patients that undergo gadoxetic acid-enhanced MRI.
    Eiras-Araújo AL; Parente DB; da Silva AC; da Motta Rezende GF; Mendes GB; Luiz RR; de Oliveira Souza R; da Costa Generalis S; Rodrigues RS; Perez RM
    Eur Radiol; 2023 Jul; 33(7):5142-5149. PubMed ID: 36651953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy of the gadoxetic acid MRI-derived relative enhancement index (REI) and functional liver imaging score (FLIS) in predicting liver function: validation with Albumin-Bilirubin (ALBI) grade.
    Eryuruk U; Tasdemir MN; Karasu HI; Aslan S
    Abdom Radiol (NY); 2024 May; 49(5):1456-1466. PubMed ID: 38653813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine.
    Khouri Chalouhi C; Vernuccio F; Rini F; Duca P; Tuscano B; Brancatelli G; Vanzulli A
    Eur Radiol; 2019 Jun; 29(6):3090-3099. PubMed ID: 30547205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biliary tract enhancement in gadoxetic acid-enhanced MRI correlates with liver function biomarkers.
    Noda Y; Goshima S; Kajita K; Kawada H; Kawai N; Koyasu H; Matsuo M; Bae KT
    Eur J Radiol; 2016 Nov; 85(11):2001-2007. PubMed ID: 27776652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D T1 relaxometry pre and post gadoxetic acid injection for the assessment of liver cirrhosis and liver function.
    Besa C; Bane O; Jajamovich G; Marchione J; Taouli B
    Magn Reson Imaging; 2015 Nov; 33(9):1075-1082. PubMed ID: 26119422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver volumetry in cirrhotic patients with or without hepatocellular carcinoma: Its correlation with Child-Pugh, model for end-stage liver diseases and indocyanine green dye test.
    Patidar Y; Mittal K; Patel RK; Thomas SS; Sarin SK
    Indian J Gastroenterol; 2024 Aug; 43(4):760-767. PubMed ID: 38349461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of functional liver imaging scores (FLIS) derived from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Child-Pugh score and FLIS.
    Lee HJ; Hong SB; Lee NK; Kim S; Seo HI; Kim DU; Han SY; Choo KS
    Eur Radiol; 2021 Nov; 31(11):8606-8614. PubMed ID: 33881570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume-assisted estimation of liver function based on Gd-EOB-DTPA-enhanced MR relaxometry.
    Haimerl M; Schlabeck M; Verloh N; Zeman F; Fellner C; Nickel D; Barreiros AP; Loss M; Stroszczynski C; Wiggermann P
    Eur Radiol; 2016 Apr; 26(4):1125-33. PubMed ID: 26186960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Posthepatectomy Liver Failure: MRI With Hepatocyte-Specific Contrast Agent Versus Indocyanine Green Clearance Test.
    Kim DK; Choi JI; Choi MH; Park MY; Lee YJ; Rha SE; Jung SE
    AJR Am J Roentgenol; 2018 Sep; 211(3):580-587. PubMed ID: 29995498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing liver function: diagnostic efficacy of parenchymal enhancement and liver volume ratio of Gd-EOB-DTPA-enhanced MRI study during interstitial and hepatobiliary phase.
    Ippolito D; Pecorelli A; Famularo S; Bernasconi D; Orsini EB; Giani A; Romano F; Talei Franzesi C; Sironi S
    Abdom Radiol (NY); 2019 Apr; 44(4):1340-1349. PubMed ID: 30411177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.
    Öcal O; Peynircioglu B; Loewe C; van Delden O; Vandecaveye V; Gebauer B; Zech CJ; Sengel C; Bargellini I; Iezzi R; Benito A; Schütte K; Gasbarrini A; Seidensticker R; Wildgruber M; Pech M; Malfertheiner P; Ricke J; Seidensticker M
    Eur Radiol; 2022 Feb; 32(2):1320-1329. PubMed ID: 34467453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?
    Sandrasegaran K; Cui E; Elkady R; Gasparis P; Borthakur G; Tann M; Liangpunsakul S
    Eur Radiol; 2018 Oct; 28(10):4215-4224. PubMed ID: 29651764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI.
    Ippolito D; Famularo S; Giani A; Orsini EB; Pecorelli A; Pinotti E; Gandola D; Romano F; Sironi S; Bernasconi DP; Gianotti L
    Dig Liver Dis; 2019 Oct; 51(10):1438-1445. PubMed ID: 31153787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases.
    Beer L; Mandorfer M; Bastati N; Poetter-Lang S; Tamandl D; Stoyanova DP; Elmer MC; Semmler G; Simbrunner B; Hodge JC; Sirlin CB; Reiberger T; Ba-Ssalamah A
    Eur Radiol; 2019 Dec; 29(12):6600-6610. PubMed ID: 31001679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness comparison of indocyanine green retention test with the cirrhotic severity scoring in evaluating the pathological severity of liver cirrhosis in patients with hepatocellular carcinoma and Child-Pugh grade A liver function.
    Gu J; Zhang E; Liang B; Zhang Z; Chen X; Huang Z
    World J Surg Oncol; 2020 Apr; 18(1):79. PubMed ID: 32326968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis.
    Stauber RE; Wagner D; Stadlbauer V; Palma S; Gurakuqi G; Kniepeiss D; Iberer F; Smolle KH; Haas J; Trauner M
    Liver Int; 2009 Nov; 29(10):1516-20. PubMed ID: 19732329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the efficacy of functional liver imaging score (FLIS) obtained from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Albumin-Bilirubin (ALBI) grade and FLIS.
    Aslan S; Eryuruk U; Tasdemir MN; Cakir IM
    Abdom Radiol (NY); 2022 Jul; 47(7):2325-2334. PubMed ID: 35672474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple Method for evaluating the degree of liver parenchymal enhancement in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging.
    Tamada T; Ito K; Yamamoto A; Yasokawa K; Higaki A; Kanki A; Sato T; Taniomoto D; Higashi H
    J Magn Reson Imaging; 2013 May; 37(5):1115-21. PubMed ID: 23148041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of liver function using liver parenchyma, spleen and portal vein signal intensities during the hepatobiliary phase in Gd-EOB-D TPA-enhanced MRI.
    Yang M; Zhang Y; Zhao W; Cheng W; Wang H; Guo S
    BMC Med Imaging; 2020 Oct; 20(1):119. PubMed ID: 33081713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
    Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
    Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.